Sepsis, September 17 edition

In the prospective multicenter PROGRESS randomized trial, 1,373 patients with suspected sepsis were assigned in a 3:1 ratio to droplet digital PCR or standard care and followed for 90 days. Droplet digital PCR produced a markedly higher pathogen-detection positivity rate than standard care, directly addressing the diagnostic and antibiotic-management limitations of conventional testing.

Impact: This is a relatively large prospective randomized evaluation of a molecular diagnostic strategy intended to provide actionable pathogen information during suspected sepsis. Its multicenter design and direct comparison with standard care increase the relevance of the findings to antimicrobial stewardship and early sepsis management.

Clinical Implications: Droplet digital PCR may support faster and more sensitive pathogen detection and could help clinicians refine antimicrobial selection or de-escalation. Before routine implementation, effects on antibiotic exposure, mortality, costs, turnaround time, and performance across different laboratories and pathogen spectra should be confirmed.

Future Directions: Future studies should report antibiotic de-escalation, time to effective therapy, antimicrobial resistance, costs, and patient-centered outcomes. Independent implementation trials across hospitals with different microbiology infrastructure are needed to determine whether improved detection translates into better survival or antibiotic stewardship.

This mechanistic preclinical study developed nanoparticles that selectively deliver stabilized FOXF1 mRNA to pulmonary endothelial cells in neonatal mice with lipopolysaccharide-induced pediatric acute respiratory distress syndrome. Treatment reduced vascular leakage and endothelial apoptosis, improved barrier function, and increased survival, with restoration of BCL2 expression identified as a potential mechanism.

Impact: The study addresses a major unmet need in pediatric sepsis-associated lung injury by combining cell-selective delivery with a lung-repair transcription factor. It provides in vivo evidence for a potentially disease-modifying approach rather than only supportive respiratory management.

Clinical Implications: FOXF1 mRNA nanoparticles could eventually represent a targeted therapy for pediatric acute lung injury or pediatric acute respiratory distress syndrome, particularly when endothelial barrier failure is prominent. The findings are not yet sufficient for human use because biodistribution, dosing, repeated administration, long-term safety, and efficacy in clinically relevant polymicrobial sepsis models remain to be established.

Future Directions: Future research should test the platform in polymicrobial sepsis and clinically relevant pediatric lung-injury models, define pharmacokinetics and biodistribution, assess immune and off-target effects, and evaluate manufacturing scalability. Translation will require large-animal safety studies and comparison with current pediatric respiratory-support strategies.

In a multicenter before-and-after controlled study of 869 patients with abdominal sepsis, a nurse-led respiratory care bundle was associated with a reduction in pneumonia from 42.2% to 25.6%. The intervention was also associated with shorter hospital stay and lower 28-day mortality, and results remained consistent across multivariable adjustment, propensity methods, inverse probability weighting, generalized estimating equations, mixed-effects models, and bootstrap analyses.

Impact: The study evaluates a relatively low-cost, nurse-delivered intervention with direct potential for implementation in intensive care settings. The large multicenter sample and extensive sensitivity analyses strengthen the association, although the nonrandomized before-and-after design limits causal certainty.

Clinical Implications: A structured nurse-led respiratory bundle may be considered as part of pneumonia-prevention protocols for critically ill patients with abdominal sepsis. Local adaptation, staff training, monitoring of adherence, and prospective evaluation are needed before attributing the observed mortality reduction solely to the intervention.

Future Directions: A stepped-wedge or cluster-randomized trial should evaluate the bundle with standardized intervention components, adherence measures, and prespecified safety outcomes. Future work should also identify which bundle elements are most effective, assess resource requirements, and determine whether benefits extend to other sepsis sources and healthcare systems.